Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Cara Therapeutics, Inc.
  6. News
  7. Summary
    CARA   US1407551092

CARA THERAPEUTICS, INC.

(CARA)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
9.390 USD   +2.96%
06/07CARA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/06Amarin Names Tom Reilly Finance Chief
MT
06/06Cara Therapeutics CFO Thomas Reilly Resigns
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cara Therapeutics' Korsuva Injection Receives TDAPA Reimbursement

12/20/2021 | 08:35am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
CARA THERAPEUTICS, INC. 2.96% 9.39 Delayed Quote.-22.91%
VIFOR PHARMA AG 0.15% 171.95 Delayed Quote.5.98%
All news about CARA THERAPEUTICS, INC.
06/07CARA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/06Amarin Names Tom Reilly Finance Chief
MT
06/06Cara Therapeutics CFO Thomas Reilly Resigns
MT
06/03CARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/03Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Offic..
CI
05/17Cara Therapeutics to Present at Upcoming Investor Conferences
GL
05/10TRANSCRIPT : Cara Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conferenc..
CI
05/09TRANSCRIPT : Cara Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09CARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/09CARA : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on CARA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 75,3 M - -
Net income 2022 -69,1 M - -
Net cash 2022 190 M - -
P/E ratio 2022 -7,34x
Yield 2022 -
Capitalization 503 M 503 M -
EV / Sales 2022 4,16x
EV / Sales 2023 2,05x
Nbr of Employees 84
Free-Float 83,7%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,39 $
Average target price 24,25 $
Spread / Average Target 158%
EPS Revisions
Managers and Directors
Christopher Posner President, Chief Executive Officer & Director
Richard Makara VP, Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Scott M. Terrillion Secretary & Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
CARA THERAPEUTICS, INC.-22.91%503
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574